A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Prithviraj Bose; Srdan Verstovsek; Jorge E. Cortes; Susan Tse; Yvonne Gasior; Nitin Jain; Elias J. Jabbour; Zeev Estrov; Yesid Alvarado; Courtney D. DiNardo; Naveen Pemmaraju; Steven M. Kornblau; Tapan M. Kadia; Naval G. Daver; Kiran Naqvi; Nicholas J. Short; Lucia Masarova; John Villareal; Sherry A. Pierce; Graciela Nogueras-Gonzalez; Xuelin Huang; Guillermo Garcia-Manero; Hagop M. Kantarjian; Farhad Ravandi

doi:10.1038/s41375-020-0778-0

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Prithviraj Bose
, Srdan Verstovsek
, Jorge E. Cortes
, Susan Tse
, Yvonne Gasior
, Nitin Jain
, Elias J. Jabbour
, Zeev Estrov
, Yesid Alvarado
, Courtney D. DiNardo
, Naveen Pemmaraju
, Steven M. Kornblau
, Tapan M. Kadia
, Naval G. Daver
, Kiran Naqvi
, Nicholas J. Short
, Lucia Masarova
, John Villareal
, Sherry A. Pierce
, Graciela Nogueras-Gonzalez

Xuelin Huang, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi

Research output: Contribution to journal › Letter › peer-review

45 Scopus citations

Original language	English (US)
Pages (from-to)	2489-2492
Number of pages	4
Journal	Leukemia
Volume	34
Issue number	9
DOIs	https://doi.org/10.1038/s41375-020-0778-0
State	Published - Sep 1 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-020-0778-0

Cite this

Bose, P., Verstovsek, S., Cortes, J. E., Tse, S., Gasior, Y., Jain, N., Jabbour, E. J., Estrov, Z., Alvarado, Y., DiNardo, C. D., Pemmaraju, N., Kornblau, S. M., Kadia, T. M., Daver, N. G., Naqvi, K., Short, N. J., Masarova, L., Villareal, J., Pierce, S. A., ... Ravandi, F. (2020). A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 34(9), 2489-2492. https://doi.org/10.1038/s41375-020-0778-0

Bose, P, Verstovsek, S, Cortes, JE, Tse, S, Gasior, Y, Jain, N, Jabbour, EJ, Estrov, Z, Alvarado, Y, DiNardo, CD, Pemmaraju, N, Kornblau, SM, Kadia, TM, Daver, NG, Naqvi, K, Short, NJ, Masarova, L, Villareal, J, Pierce, SA, Nogueras-Gonzalez, G, Huang, X, Garcia-Manero, G, Kantarjian, HM & Ravandi, F 2020, 'A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia', Leukemia, vol. 34, no. 9, pp. 2489-2492. https://doi.org/10.1038/s41375-020-0778-0

@article{bd90f0afff4e4513a254fb6523f93215,

title = "A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia",

author = "Prithviraj Bose and Srdan Verstovsek and Cortes, \{Jorge E.\} and Susan Tse and Yvonne Gasior and Nitin Jain and Jabbour, \{Elias J.\} and Zeev Estrov and Yesid Alvarado and DiNardo, \{Courtney D.\} and Naveen Pemmaraju and Kornblau, \{Steven M.\} and Kadia, \{Tapan M.\} and Daver, \{Naval G.\} and Kiran Naqvi and Short, \{Nicholas J.\} and Lucia Masarova and John Villareal and Pierce, \{Sherry A.\} and Graciela Nogueras-Gonzalez and Xuelin Huang and Guillermo Garcia-Manero and Kantarjian, \{Hagop M.\} and Farhad Ravandi",

note = "Funding Information: Acknowledgements This study was supported, in part, by Incyte Corporation and by the MD Anderson Cancer Center Support Grant from the National Cancer Institute (National Institutes of Health), P30 CA016672.",

year = "2020",

month = sep,

day = "1",

doi = "10.1038/s41375-020-0778-0",

language = "English (US)",

volume = "34",

pages = "2489--2492",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

AU - Bose, Prithviraj

AU - Verstovsek, Srdan

AU - Cortes, Jorge E.

AU - Tse, Susan

AU - Gasior, Yvonne

AU - Jain, Nitin

AU - Jabbour, Elias J.

AU - Estrov, Zeev

AU - Alvarado, Yesid

AU - DiNardo, Courtney D.

AU - Pemmaraju, Naveen

AU - Kornblau, Steven M.

AU - Kadia, Tapan M.

AU - Daver, Naval G.

AU - Naqvi, Kiran

AU - Short, Nicholas J.

AU - Masarova, Lucia

AU - Villareal, John

AU - Pierce, Sherry A.

AU - Nogueras-Gonzalez, Graciela

AU - Huang, Xuelin

AU - Garcia-Manero, Guillermo

AU - Kantarjian, Hagop M.

AU - Ravandi, Farhad

N1 - Funding Information: Acknowledgements This study was supported, in part, by Incyte Corporation and by the MD Anderson Cancer Center Support Grant from the National Cancer Institute (National Institutes of Health), P30 CA016672.

PY - 2020/9/1

Y1 - 2020/9/1

UR - https://www.scopus.com/pages/publications/85089383115

UR - https://www.scopus.com/pages/publications/85089383115#tab=citedBy

U2 - 10.1038/s41375-020-0778-0

DO - 10.1038/s41375-020-0778-0

M3 - Letter

C2 - 32099037

AN - SCOPUS:85089383115

SN - 0887-6924

VL - 34

SP - 2489

EP - 2492

JO - Leukemia

JF - Leukemia

IS - 9

ER -

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this